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background: Although antiplatelet agents are recommended for patients with peripheral arterial disease (PAD), there is little data on the effect of 
dual antiplatelet therapy with aspirin and clopidogrel (DAPT) compared to aspirin monotherapy.
methods: 629 patients with claudication or critical limb ischemia who underwent angiography from 2006-2013 were included. The prevalence of 
patients taking aspirin vs. DAPT was assessed at the time of angiography and monthly for up to three years. A propensity model was constructed to 
adjust for baseline demographic characteristics, and a Cox regression model was used to assess the effect of DAPT as a time-varying covariate on 
the incidence of major adverse cardiovascular events (MACE).
results: At baseline, 348 patients were taking DAPT and 281 were taking aspirin monotherapy. Patients prescribed DAPT were more likely to have 
a history of diabetes (54% vs. 45%, p=0.02) or coronary artery disease (56% vs. 45%, p = 0.007). During three-year follow-up, 50 events (20%) 
occurred in the DAPT group, versus 50 (29%) in the ASA monotherapy group. After propensity weighting, DAPT use was associated with a decreased 
risk of MACE (adjusted HR 0.65, 95% CI 0.44-0.96) and overall mortality (adjusted HR 0.55, 95% CI 0.35-0.89). There was no association between 
DAPT use and rates of major amputation (9% vs. 7%, p=0.7).
conclusions: Dual antiplatelet therapy may be associated with reduced rates of MACE and mortality among patients with symptomatic peripheral 
arterial disease.
 
